Weekly Gravy « Weekly Gravy

All Sauce from Weekly Gravy:

For decades, millions of Americans popped a low-dose aspirin each day to lower their heart risks. Then, accumulated data prompted the nation’s two leading cardiology groups — the American College of Cardiology and the American Heart Association — to overturn advisories in 2019 and recommend against daily aspirin, citing a risk for bleeding that exceeded any benefit for most people. Trouble is, many Americans aren’t heeding that message and continue to take the daily pill, a new survey finds. The survey, from a sample representing over 150 million U.S. adults, found that almost a third of heart-healthy people age 60 or older said they took a daily low-dose (81milligrams) aspirin each day in 2021. That’s about 18.5 million older Americans, said a team led by Dr. Mohak Gupta. He’s a physician in internal medicine who conducted the study while at the Cleveland Clinic. He’s now practicing at Houston Methodist. Add in folks under 60 and the number rises to more than 25.6 million Americans taking daily aspirin, the researchers estimated. Given aspirin’s now dubious risk-benefit ratio for folks at average heart risk, “our findings highlight the urgent need for physicians to inquire about aspirin use, including self-use, and engage in risk–benefit discussions to reduce inappropriate use for primary prevention in older adults,” the researchers said. They published their findings June 24 in the Annals of… read on > read on >

Losing weight can protect you against cancers related to obesity, a new study finds. Obesity has been linked to higher risk of at least 13 types of cancer, researchers said. This is largely due to excess levels of hormones like estrogen and insulin. But study results show that dropping pounds can improve a person’s odds against developing these cancers, including breast, kidney, ovary, liver and pancreatic cancers. “This study reinforces how crucial it is to treat obesity as a chronic disease,” said researcher Dr. Kenda Alkwatli, a clinical fellow at Cleveland Clinic. “We are hopeful that these results can help us better understand how we can use weight loss to address co-morbidities, including cancer in patients with obesity.” For the study, researchers evaluated the electronic health records of more than 100,000 obese patients at the Cleveland Clinic, of whom more than 5,300 developed cancer. Researchers tracked changes in BMI at three-, five- and 10-year intervals prior to a person’s cancer diagnosis and compared them against controls. They found that losing weight could reduce a person’s risk of developing most obesity-related cancers within a five-year span. For example, the risk of kidney cancer dropped within three years and endometrial cancer at three and five years. Multiple myeloma risk fell within 10 years. What’s more, losing weight also appeared to protect people against a range of 16… read on > read on >

A well-established cholesterol-lowering drug appears to significantly slow the progression of a diabetes-related eye disease, a new trial shows. Fenofibrate (Tricor) has been approved since 2004 as a means of lowering cholesterol. Now, this new study shows that fenofibrate also can reduce the progression of diabetic retinopathy by 27% compared to placebo. The findings were published June 21 in the journal NEJM Evidence and presented simultaneously at the American Diabetes Association’s annual meeting in Orlando, Fla. “Diabetic retinopathy remains a leading cause of visual loss and we need simple strategies that can be widely used to reduce the progression of diabetic eye disease,” said researcher David Preiss, an associate professor at Oxford Population Health in the UK. The results from the new trial “suggest that fenofibrate may provide a valuable addition to treat people with diabetic retinopathy,” Preiss added in a meeting news release. Diabetic retinopathy occurs when elevated blood sugar levels damage blood vessels in the back of the eye. The vessels start to swell and leak, eventually leading to blurry vision, blank spots and blindness. For this study, researchers recruited 1,151 adults in Scotland who had developed early diabetic retinopathy or macular degeneration. They were randomly assigned to take either fenofibrate tablets or a placebo. Over four years, nearly 23% of people taking fenofibrate had their eye disease worsen, compared with 29% on… read on > read on >

For the first time since the pandemic, it got a little safer to cross America’s streets in 2023, new statistics show. According to data released Monday from the Governors Highway Safety Association (GHSA), 7,318 American pedestrians were killed by motor vehicles last year — a dip of 5.4% from 2022 and the first such decline seen since the pandemic ended. But it’s no time for celebration: The 2023 number for pedestrian deaths is still 14.1% above pre-pandemic levels. Still, the news is somewhat heartening, said GHSA Chief Executive Officer Jonathan Adkins. “A decline in pedestrian deaths offers hope that, after years of rising fatalities, a new trend is starting,” he said in a GHSA news release. “Each death is tragic and preventable. We know how to improve safety for people walking — more infrastructure, vehicles designed to protect people walking, lower speeds and equitable traffic enforcement. It will take all this, and more, to keep the numbers going in the right direction.” The new data comes from the State Highway Safety Offices (SHSOs) in all 50 states and the District of Columbia, the GHSA said. The report also gave insights into how and where pedestrians are most often killed: There’s been no big change in the kinds of vehicles driven when a pedestrian dies, only that the percentage of deaths involving light trucks ( SUVs, pickups… read on > read on >

The rate of self-reported mental distress and depression among American adults who identify as transgender or gender-diverse (TGD) has more than doubled between 2014 and 2022, an analysis of federal health data reveals. During that time, “a record number of enacted laws has threatened the rights and protections of TGD people, including restricting access to gender-affirming care and permitting discrimination in public accommodations,” noted a team of researchers led by health care policy investigator Michael Liu, of Harvard Medical School. The findings are published June 24 in the journal JAMA Internal Medicine. Liu’s team tracked survey data from the federal government’s ongoing Behavioral Risk Factor Surveillance System, which follows the self-reported physical and mental health of U.S. adults over time. The analysis started in 2014, the first year in which gender identity was added to the survey, and tracked data through 2022. Liu’s team found that the “prevalence of frequent mental distress increased from 18.8% in 2014 to 38.9% in 2022” among transgender or gender-diverse people. In contrast, the rise in mental distress was less steep among cisgender people — from 11.2% to 15.5%. Depression rates among transgender and gender-diverse adults also rose sharply between 2014 and 2022 — more than doubling from 19.7% to 51.3%, Liu’s group found. Over the same time period, depression rates among cisgender adults rose only slightly, from 18.6% to… read on > read on >

The U.S. Food and Drug Administration’s decision to authorize the first menthol-flavored e-cigarettes has drawn the the ire of health advocates who say the decision undermines efforts to end the youth vaping epidemic in America. In its approval of four flavored vaping products made by Njoy, the agency defended its decision. “Based upon our rigorous scientific review, in this instance, the strength of evidence of benefits to adult smokers from completely switching to a less harmful product was sufficient to outweigh the risks to youth,” Matthew Farrelly, director of the Office of Science in the FDA’s Center for Tobacco Products, said in an agency news release announcing the authorization. But that argument did not convince anti-tobacco groups and health advocates. “The FDA’s decision today to authorize the sale of four menthol-flavored e-cigarettes made by Njoy — the first time the agency has authorized the sale of any flavored e-cigarettes — is deeply troubling given the extensive scientific evidence that menthol is a flavor that appeals to kids and the FDA’s repeated conclusions that flavored e-cigarettes, including menthol-flavored products, have driven youth e-cigarette use,” Yolonda Richardson, president and CEO of the Campaign for Tobacco-Free Kids, said in a statement. “The scientific evidence demonstrates that menthol is a flavor that appeals to kids, and the tobacco industry has a long history of using menthol flavoring to attract… read on > read on >

Specific steps can be taken to reduce the risk of potentially fatal reactions to anti-seizure medications, researchers report in a new review. Performing blood tests, asking patients about risk factors and modifying dosages all can reduce reaction risk for drugs that millions of Americans take for epilepsy and other conditions, researchers said. However, rashes and skin reactions in newly medicated patients still require prompt medical attention, results show. Rashes are common with anti-seizure meds, occurring in 2% to 16% of patients, depending on the drug, researchers said in background notes. Roughly 5% of these rashes indicate a life-threatening condition, researchers added. The FDA recently issued a warning about serious reactions to two anti-seizure drugs, levetiracetam and clobazam, the researchers noted. “Dangerous reactions are rare, but patients and caregivers should understand the risk and how to respond if side effects occur,” said lead researcher Dr. Ram Mani, chief of the adult epilepsy division at Rutgers Robert Wood Johnson Medical School in New Jersey. For the new report, published recently in the journal Current Treatment Options in Neurology, researchers analyzed and combined published data on individual anti-seizure drugs, distinguishing the different rashes and their triggers. Genetics can increase a person’s risk of a severe rash, as can interactions between the anti-seizure meds and other drugs, researchers found. Users also are at higher risk if they use aromatic… read on > read on >

When a couple can’t get pregnant, the focus is often on the prospective mom, but that needs to change, a Houston urologist says. “Both partners need evaluation,” said Dr. Larry Lipschultz, a professor of urology at Baylor College of Medicine in Houston. “With fertility, you can’t finger point. It’s not a male or female problem as much as it needs to be considered a couple’s problem.” Men who are infertile have no way to know unless they’ve had specific surgeries or an accident involving their testicles. The only sign is being unable to get a woman pregnant. A fertility test can confirm this. Once a man hits his 50s, his fertility drops. It’s not as dramatic a decline as that which a woman experiences during menopause — rather, it happens little by little. Guys who are obese or who put on weight may also have trouble producing enough sperm. A doctor might recommend losing weight, to boost production of male hormones. A diet rich in foods containing antioxidants may also be suggested. “The issue with obesity is that fat metabolizes testosterone to estrogen, which is bad for sperm production,” Lipschultz said in a Baylor news release. “Generally, trying to maintain a good bodyweight through exercise and proper diet is going to be helpful.” Keep in mind that the testosterone should not come from an outside… read on > read on >

The pandemic highlighted the risk that air travel carries for the spread of infectious diseases, and that risk remains even though the health emergency has passed. “Airplanes have many touch points that are perfect for the transfer of bacteria or viruses,” said Dr. Mike Ren, an assistant professor of family and community medicine at Baylor College of Medicine in Houston. “You don’t want to get sick while on vacation and prevent your chance for relaxation or come back with a cold or something worse.” The risk of catching a cold or flu starts even before a person boards their flight, Ren said. Ride-sharing services transport hundreds of strangers each day, and thousands pass through airports on their way to and from their terminal. But a few common practices can help protect you from catching something, Ren said: Use sanitizing wipes to clean the most-touched places on a plane — seats, tray tables, seat back pockets, arm rests, flight attendant call buttons, air vents and lavatory door handles Apply hand sanitizer or wash your hands regularly, particularly prior to eating a snack or after touching check-in kiosks, handling boarding passes or using the airplane or airport bathroom Keep boarding passes and other documents on your smartphone, to reduce the number of times you touch surfaces in the airport and on the plane Wear a mask through… read on > read on >

A medication used to manage type 2 diabetes has been found effective in treating sleep apnea. The worldwide clinical trial demonstrates that tirzepatide significantly lowers breathing interruptions during sleep, a key indicator of the severity of a patient’s obstructive sleep apnea (OSA). Tirzepatide is one of the class of blockbuster GLP-1 medicines, sold as Mounjaro to fight diabetes and as Zepbound to help with weight loss. “This study marks a significant milestone in the treatment of OSA, offering a promising new therapeutic option that addresses both respiratory and metabolic complications,” said study leader Dr. Atul Malhotra, director of sleep medicine at UC San Diego Health. OSA is characterized by repeated episodes of irregular breathing during sleep due to total or partial blockage of the upper airway. It can result in reduced oxygen levels in the blood and has been linked to an increased risk for high blood pressure, heart disease and other heart-related complications. More than 900 million people worldwide are believed to have OSA, and the 469 participants in this study were recruited from the United States and eight other countries. All were clinically obese and had moderate-to-severe sleep apnea. Some used continuous positive airway pressure (CPAP) treatment, in which a machine maintains an open airway during sleep. All were given 10 or 15 milligrams (mg) of tirzepatide or a placebo. Over the course… read on > read on >

Weekly Gravy

Look Good – Feel Good – Feed Good

A little about: Weekly Gravy

All Sauce from Weekly Gravy:

Despite Falling Out of Favor With Doctors, Daily Aspirin Still Popular

Healthy Weight Loss Could Lower Your Odds for Cancer

Cholesterol Med Might Slow Vision Loss in People With Diabetes

U.S. Pedestrian Deaths Decline for First Time Since Pandemic

Rates of Distress, Depression Have Doubled Among Transgender Americans Since 2014

FDA’s Move to OK First Menthol Vapes Is Big Mistake, Health Advocates Say

Anti- Seizure Meds Are Crucial, But Can Trigger Severe Reactions

Dad Facts: What Men Need to Know About Their Fertility

Plane Hygiene: Staying Healthy at 35,000 Feet

GLP-1 Medicine Mounjaro May Be First Drug to Ease Sleep Apnea

Share on Mastodon